Общество с ограниченной ответственностью Издательско-торговая корпорация "Дашков и К". 2018. 411 с.
Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical 177Lu-DOTA-PSMA
The therapeutic efficacy of a Russian radiopharmaceutical Lu-177-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with Lu-177-DOTA-PSMA were significantly lower than in animals of the control group. There were no significant differences in the values of tumor growth inhibition between the groups of animals receiving 3.7 or 7.4 MBq of Lu-177-DOTA-PSMA.
Авторы
Tishchenko V.K. 1 , Vlasova O.P. 1, 2 , Lebedeva A.A. 1 , Fedorova A.V. 1 , Pankratov A.A. 3 , Morozova N.B. 3 , Kuzenkova K.A. 1 , Stepchenkova E.D. 1 , Shegai P.V. 1, 2 , Ivanov S.A. 1, 4 , Kaprin A.D. 2, 3, 4
Издательство
Springer New York Consultants Bureau
Номер выпуска
2
Язык
English
Страницы
224-226
Статус
Published
Том
176
Год
2023
Организации
- 1 Minist Hlth Russian Federat, Natl Med Res Radiol Ctr, A Tsyb Med Radiol Res Ctr, Affiliated Branch, Obninsk, Russia
- 2 Minist Hlth Russian Federat, Natl Med Res Radiol Ctr, Obninsk, Russia
- 3 Minist Hlth Russian Federat, P A Gertsen Moscow Res Oncol Inst, Branch Natl Med Res Radiol Ctr, Moscow, Russia
- 4 RUDN Univ, Patrice Lumumba PeoplesFriendship Univ Russia, Moscow, Russia
Ключевые слова
prostate-specific membrane antigen; metastatic castrate-resistant prostate cancer; radioligand therapy; lutetium-177; radiopharmaceutical
Поделиться
Другие записи
Вестник Волгоградского государственного университета. Серия 2: Языкознание. Том 23. 2024. С. 181-192